Safety Shot® Clinical Trial Demonstrates Significant Reduction in Blood Alcohol Levels and Hangover Symptoms
SCOTTSDALE, Ariz., March 4, 2025 — Safety Shot, Inc. (Nasdaq: SHOT), a company specializing in wellness and dietary supplements, has announced the publication of compelling clinical trial results showing the effectiveness of its product, Safety Shot®, in reducing the negative impacts of acute alcohol consumption. The peer-reviewed, randomized, double-blind, placebo-controlled study, published in the Journal of Nutrition and Dietary Supplements (Volume 17, February 26, 2025, Pages 43-62), revealed statistically significant reductions in blood alcohol concentration (BAC), breath alcohol concentration (BrAC), and hangover symptoms for participants using Safety Shot® compared to placebo.
Breakthrough Human Clinical Evidence for a Dietary Supplement
This trial marks the first-ever human clinical investigation to validate a dietary supplement blend’s efficacy in mitigating the acute effects of alcohol in humans. Unlike earlier research predominantly based on animal models, Safety Shot’s human trial delivers more relevant and dependable data. This positions the product as a groundbreaking advancement for consumers aiming to address and manage the adverse aftereffects commonly associated with alcohol use.
Study Design and Key Findings
The trial was conducted by the Center for Applied Health Sciences (CAHS), an independent third-party research institution, involving a diverse group of healthy adults varying in age, ethnicity, body composition, and sex. Participants were administered alcohol and then randomized to receive either Safety Shot® or a placebo in a crossover design, allowing each individual to serve as their own control. The study’s double-blind and randomized placebo-controlled aspects ensured scientific rigor and minimized variability.
Key results from the trial included:
-
Rapid Reduction of Alcohol Levels: Participants receiving Safety Shot® showed a significant decrease in blood and breath alcohol concentrations within just 30 minutes post-consumption, with effects lasting up to 240 minutes. These reductions were statistically significant compared to placebo (p < 0.05).
-
Enhanced Activity of Aldehyde Dehydrogenase: Safety Shot® was associated with significant increases in aldehyde dehydrogenase enzyme activity (p = 0.004 for AUC and p = 0.010 for Cmax). By temporarily elevating acetaldehyde levels, the supplement expedited the metabolic processing of alcohol’s toxic intermediates, promoting faster detoxification.
-
Improvement in Hangover Symptoms: Participants reported noticeable alleviation of typical hangover symptoms, including decreased headache severity, reduced fatigue, better energy levels, and improved concentration. These improvements were consistently observed at multiple time intervals throughout the study.
- Increased Urine Output: Greater urine excretion was recorded, notably at 60 minutes, suggesting improved elimination of alcohol from the body when participants used Safety Shot®.
Dr. Tim Ziegenfuss, CEO of CAHS, highlighted the implications: “The reductions seen in breath and blood alcohol concentrations along with subjective and physiological benefits underscore Safety Shot’s potential as a beneficial supplement for people who consume alcohol.”
Company Perspective on the Research and Market Opportunity
Jarrett Boon, CEO of Safety Shot, emphasized the significance of these findings: “This clinical validation in a peer-reviewed setting is a pivotal achievement for Safety Shot. It confirms that over-the-counter solutions exist to help mitigate alcohol’s negative effects safely and effectively, allowing individuals better control over their drinking experience.”
The study was designed with broad inclusivity to reflect real-world conditions as closely as possible. Although ethical limits restricted the amount of alcohol consumed, participants represented a wide demographic range, enhancing the generalizability of results.
Safety Shot’s entry into the hangover remedy market arrives at a time of rapid growth. The global market for hangover cures is projected to expand at a compound annual growth rate of 14.1% through 2030, potentially exceeding $6 billion by 2032. Contributing factors include rising alcohol consumption worldwide and increased awareness of the harmful effects of hangovers, leading to greater demand for effective mitigation products. Safety Shot®’s scientifically backed formula uniquely positions it to capture a substantial share of this expanding sector.
About Safety Shot, Inc.
Safety Shot, Inc. is a wellness and dietary supplement company devoted to creating innovative products that support healthy alcohol metabolism and overall well-being. Their flagship product, Safety Shot®, is a proprietary blend featuring natural ingredients such as red ginseng, N-acetyl cysteine, dandelion extract, milk thistle, along with antioxidants, anti-inflammatory agents, and nootropics. This combination is designed to aid the body’s detoxification processes, reduce oxidative stress, and enhance energy and mental clarity.
Safety Shot® is currently available online and is planned for broader distribution through retailers, restaurants, and bars throughout 2025.
Contact Information
For investor relations and media inquiries, Safety Shot, Inc. can be reached through their appointed representatives.
This landmark study confirms Safety Shot® as a scientifically validated dietary supplement capable of accelerating the reduction of blood alcohol content and alleviating hangover symptoms, representing a significant advancement in alcohol-related wellness solutions.